// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Anastasiya A. Chumanevich1, Anusha Chaparala1, Erin E. Witalison1, Hossam Tashkandi1, Anne B. Hofseth1, Corey Lane1, Edsel Pena2, Piaomu Liu2, Doug L. Pittman1, Prakash Nagarkatti3, Mitzi Nagarkatti3, Lorne J. Hofseth1 and Alexander A. Chumanevich1 1 Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, SC, USA 2 Department of Statistics, University of South Carolina, Columbia, SC, USA 3 School of Medicine, University of South Carolina, Columbia, SC, USA Correspondence to: Alexander A. Chumanevich, email: // <![CDATA[ mail("chumanev","mailbox.sc",14,"") // ]]> Keywords: colitis, colon, inflammation, dextran sulfate sodium, CAM, FDA Received: November 11, 2016 Accepted: November 15, 2016 Published: December 10, 2016